MedTrace Logo

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

NCT03417544 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-04-27

Study results available
· View outcomes & findings →

Summary

This research study is studying a drug called atezolizumab as a possible treatment HER2-positive metastatic breast cancer (MBC) that has spread to the brain.

The names of the study drugs involved in this study are:

* Atezolizumab
* Pertuzumab
* Trastuzumab

Conditions

Interventions

DRUG

ATEZOLIZUMAB

(IV) every 3 weeks

DRUG

PERTUZUMAB

Loading dose, followed every 3 weeks thereafter by a predetermined dose in the protocol via IV

DRUG

TRASTUZUMAB

Predetermined dose per protocol via IV, weekly for 24 weeks and after every 3 weeks

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Nancy Lin, MD

    lead OTHER

Principal Investigators

  • Nancy Lin, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-21
Primary Completion
2020-05-20
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03417544 on ClinicalTrials.gov